Eleven Biotherapeutics Presents Data on Novel Protein Therapeutics for Treatment of Front and Back of Eye Diseases at ARVO 2014 Annual Meeting
![](/46/pdcnewsitem/03/33/04/zx5GMrPikEHFhLe.png)
Eleven Biotherapeutics, a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, has announced the presentation of data for two of its novel, protein therapeutics demonstrating the key role of cytokine biology to target both front and back of eye diseases at the Association for Research in Vision and Ophthalmology (ARVO) 2014 Annual Meeting in Orlando, FL.
Clinical data on Eleven’s lead drug candidate, EBI-005, the first IL-1 (Interleukin-1) signaling inhibitor designed for topical ocular administration, demonstrated improvements in signs and symptoms of dry eye disease (DED), including reduction in ocular pain and artificial tear use.
In addition, preclinical data on EBI-029, an IL-6 (Interleukin-6) inhibitor optimized for localized ocular administration in diabetic macular edema (DME), has demonstrated that EBI-029 potently inhibits IL-6 signaling in vitro. IL-6 is a cytokine that has previously been shown to be upregulated in DME, contributing to the angiogenic and inflammatory components of the disease and correlating with disease severity. By inhibiting IL-6, EBI-029 could offer an alternative to current standard of care, including anti-VEGF therapies.
“Proteins designed specifically as ophthalmic therapies represents an innovative approach to treating diseases of the eye with high unmet need,” said Abbie Celniker, PhD, Chief Executive Officer of Eleven Biotherapeutics. “These data demonstrate Eleven’s ability to target both front and back of eye disease by leveraging our extensive cytokine biology expertise.”
Dr Celniker continued: “The data we are presenting on our lead product candidate, EBI-005, underscores its potential utility in treating dry eye disease by inhibiting the cytokine IL-1, a key mediator of inflammation in the eye. Likewise, a correlation has been previously observed between increased IL-6 levels and disease severity in diabetic macular edema, including scenarios where VEGF inhibition treatment has been suboptimal. These data suggest the potential of IL-6 blockade with EBI-029 in treating diabetic macular edema and support further development of EBI-029 either as a stand-alone drug or in combination with VEGF blockade.”
EBI-005, a topical IL-1 receptor antagonist for the treatment of ocular surface disease, is currently being evaluated in a pivotal Phase III clinical study in subjects with DED and a Phase II clinical study in subjects with allergic conjunctivitis. EBI-029, an IL-6 receptor antagonist for localized intravitreal treatment of back of eye disease, is currently in preclinical development for the treatment of DME.
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance